Navigation Links
Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
Date:8/5/2011

SEATTLE, Aug. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Canaccord Genuity Growth Conference in Boston, MA on August 10 at 5:00 PM EDT.

The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Reports Second Quarter 2011 Financial Results
2. Dendreon to Host Conference Call on August 3, 2011 to Announce Second Quarter 2011 Financial Results
3. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
4. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
5. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
6. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
7. Dendreon Announces Webcast Presentation at Upcoming Conferences
8. Dendreon Reports First Quarter 2011 Financial Results
9. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
10. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
11. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... way of life at Meriter Hospital , a ... care to southern Wisconsin. Meriter includes a hospital, clinic, ... service. Formed from a merger of Madison General Hospital ... 430 active and associate physicians in over 30 medical ...
... from traditional paper phone bills to SBC eBill ... the "Save a StampHelp Save a Life" campaign, created in ... Inc. will contribute $1 dollar for every SBC customer that ... 15, 2004. , ,In 2004, an estimated 216,000 new cases ...
... Despite a two-year-plus economic recovery in the United States, ... which source you cite) have mysteriously failed to appear ... they not been created as expected? The list of ... recovery, uncertainty about the future, terrorism and the war ...
Cached Biology Technology:Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4Gone missing: Today jobs, tomorrow workers? 2Gone missing: Today jobs, tomorrow workers? 3
(Date:7/30/2014)... (125I) in cancer treatment has been shown to ... critical for neural transmission between the peripheral and ... from Institute of Radiation Medicine, Chinese Academy of ... implanted into rat dorsal root ganglia (DRG) to ... different radioactivity (0, 14.8, 29.6 MBq) were implanted ...
(Date:7/30/2014)... into a multitude of cells types. Researchers would like to ... of mature cells that make up the organs and other ... be long chains of sugars that dangle from proteins on ... of California, San Diego, has created synthetic molecules that can ... easily manipulated to direct the process, they report in the ...
(Date:7/30/2014)... SAN JOSE, Calif. , July 30, 2014 ... industry-academia partnership with the United States Air Force ... project proposed by Binghamton ... for human performance monitoring (HPM). The $425,000 project, ... and electronics packaging firm i3 Electronics, Inc. ( ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... life," but does today,s unprecedented level of dietary variety ... it might. According to ASN Spokesperson Shelley ... eating, itself- can trigger release of various brain chemicals, ... with drug addiction and withdrawal. And, as can happen ...
... Populations of spur-thighed tortoises ( Testudo graeca ), a species ... fires if outbreaks occur once every three decades or more. ... each fire. These are the results of a study by ... fire in the Sierra de la Carrasquilla mountains in Murcia ...
... is available in German . They live their lives ... upright position, sloths spend most of their lives hanging in trees ... slowly. Very slowly. But why are sloths so ,lazy,? And how ... lifestyle in the course of evolution? Zoologists of the Friedrich Schiller ...
Cached Biology News:Does food act physiologically like a 'drug of choice' for some? 2Tortoise populations can withstand fires every 30 years 2The decoding of slowness 2
... that has been shown to help maintain the ... by reverse transcription, in vitro RNA transcription, and ... tightly binds RNases in a 1:1 ratio. It ... as RNase A, RNase B, RNase C, and ...
...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
...
Biology Products: